Why Irbesartan/Hidroclorotiazida Normon is in shortage
supply-chain disruption — e.g. “Existe/n otro/s medicamento/s con los mismos principios activos y para la misma vía de administración.” (Spain)
Recent shortage history
Spain: resolved 2 Aug 2026 (began 8 Jul 2026)
Spain: resolved 12 Jan 2026 (began 21 Dec 2025)
Spain: resolved 20 Oct 2025 (began 7 Oct 2025)
Spain: resolved 29 Oct 2025 (began 2 Sept 2025)
Spain: resolved 2 Nov 2025 (began 13 May 2025)
Spain: resolved 29 Sept 2025 (began 31 Mar 2025)
Frequently asked questions
Is Irbesartan/Hidroclorotiazida Normon currently in shortage?
Yes. As of the latest regulator updates, Irbesartan/Hidroclorotiazida Normon has 4 active shortage notices across 1 country (Spain). Status is refreshed daily from official regulatory sources.
Why is Irbesartan/Hidroclorotiazida Normon in shortage?
Regulators attribute the current Irbesartan/Hidroclorotiazida Normon shortages to supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
When will the Irbesartan/Hidroclorotiazida Normon shortage be resolved?
Regulator-estimated resolution dates currently range from 9 Dec 2026 to 21 Jan 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Where does this Irbesartan/Hidroclorotiazida Normon shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Get alerted when Irbesartan/Hidroclorotiazida Normon status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Data on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.